BIOBETTERS: THE BETTER BIOLOGICS AND THEIR REGULATORY OVERVIEW
The continuous innovation of the biopharmaceutical industry has led to development of a new category of biopharmaceuticals i.e. Biobetters or Biosuperiors. Biobetters may have better efficacy, a longer half-life, lower dosing frequency, a reduced risk of immunogenicity, reduced toxicity and side effects along with lower early-stage research risk and development costs. Biobetters rather than biosimilars may capture significant share of market and are the next wave for companies to ride on. Although it sounds intuitive, biobetters will have to face various ordeals like identification of the apparent unmet need, quantification of the potential market opportunity, expensive investment in clinical trials, challenging regulatory approval, pressures of price erosion and patent litigations. Thus, development of biobetters truly requires the right balance between providing life-changing medical management for patients and maintaining an innovative pipeline for continued business success. This review will focus on technical and regulatory prospects of biobetters.
2. Sashidhar KS. Biobetters - Advent of a New Concept [Internet]. North America: Frost; 2011 Nov 28 [cited 2016 Mar 6]. Available from:
3. Stone K. Biobetter - Definition and Examples [Internet]. US: About Money; 2016 Feb 26 [cited 2016 Mar 01]. Available from:
4. Dinwoodie N.Biobetters and the Future Biologics Market. BioPharm International. 24 (11): 31-5.
5. US Code, Title 42, The Public Health and Welfare, Chap. 6A, Public Health Service, Subchapter II, General Powers and Duties, Part F, Licensing of Biological Products and Clinical Laboratories, Subpart 1, Biological Products, Sec.262, Regulation of Biological Products, (i)(2)(A).
6. Guideline on Similar Biological Medicinal Products. Evaluation of Medicines for Human Use. [Internet]. London:European Medicines Agency; 2005 Oct 30. [cited on 2016Jan]. Available from:
7. US Code, Title 42, The Public Health and Welfare, Chap. 6A, Public Health Service, Subchapter II, General Powers and Duties, Part F, Licensing of Biological Products and Clinical Laboratories, Subpart 1, Biological Products, Sec.262, Regulation of Biological Products.
8. KonskiAF.GenericBiologics.BioProcess International. 2011 Sept;9(8):34-41.
9. Gorham H. The Value of Biobetters (white paper) [Internet]. ParkLake Avenue; 2013 [cited 2016 Jan]. Available from:
10. Gormley B. A Race To Develop Better-Performing Biopharmaceuticals [Internet]. WSJ;2010 Aug [cited 2016 Mar 01]. Available from:
11. Green M. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Annals of Oncology. 2003;14(1):29-35.
12. Wu H. Balancing a biologics pipeline portfolio. Spring 11 [Internet]. Drug Discovery World; 2011 [cited 2016 Mar 01]. Available from:
13. ZwebbH. Home - GaBI Online - Generics and Biosimilars Initiative [Internet]. First world report; 2009 Dec [cited 2016 Mar 02]. Available from:
14. Haug F, Haug F. Disentangling Biobetters [Internet]. FDA Lawyers Blog; 2015 [cited 2016 Mar 02]. Available from:
15. Warmflash D. Bringing Generations Together [Internet]. World press; 2015 [cited 2016 Mar 01]. Available from:
16. Sola R, Griebenow K. Effects of glycosylation on the stability of protein pharmaceuticals. Journal of Pharmaceutical Sciences. 2009; 98(4):1223-45.
17. Aranesp® prescribing information. Amgen [Internet]. USA: Amgen Inc.: 2012May [cited 2016 Feb 12]. Available from:
18. Beck A, Cochet O, Wurch T. GlycoFi's technology to control the glycosylation of recombinant therapeutic proteins. Expert Opinion on Drug Discovery. 2009;5(1):95-111.
19. Oganesyan V, Damschroder M, Woods R, Cook K, Wu H, Dall’Acqua W. Structural characterization of a human Fc fragment engineered for extended serum half-life. Molecular Immunology. 2009; 46(8-9):1750-55.
20. Schuster M, Jost W, Mudde G, Wiederkum S, Schwager C, Janzek E et al. In vivo glyco-engineered antibody with improved lytic potential produced by an innovative non-mammalian expression system. Biotechnol J. 2007; 2(6):700-8.
21. Selvaraju R. Prolor Biotech, Inc. Biotechnology & Specialty Pharmaceutics [Internet]. 2011 Jul 12 [cited 2016 Jan13]. Available from:
22. Bioprocess online. Biobetters Q&A. [Internet]. Bioprocess online; 2011 Sept 7 [cited 2016 Feb 12]. Available from:
23. Konski AF. Generic Biologics: A Comparative Analysis of Regulatory Review. BioProcess International. 2011; 9 (8): 34-42.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The International Journal of Drug Regulatory affairs require a formal written transfer of copyright from the author(s) for each article published. We therefore ask you to complete and return this form, retaining a copy for your records. Your cooperation is essential and appreciated. Any delay will result in a delay in publication.
I/we have read and agree with the terms and conditions stated Page 2 of this agreement and I/we hereby confirm the transfer of all copyrights in and relating to the above-named manuscript, in all forms and media, now or hereafter known, to the International Journal of Drug Regulatory affairs, effective from the date stated below. I/we acknowledge that the IJDRA is relying on this agreement in publishing the above-named manuscript. However, this agreement will be null and void if the manuscript is not published in the IJDRA.
Download link for COPYRIGHT FORM